Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19380134rdf:typepubmed:Citationlld:pubmed
pubmed-article:19380134lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0027051lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0167627lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C1749467lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0700198lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0288672lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0087086lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0522523lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0595454lld:lifeskim
pubmed-article:19380134lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:19380134pubmed:issue2lld:pubmed
pubmed-article:19380134pubmed:dateCreated2009-10-5lld:pubmed
pubmed-article:19380134pubmed:abstractTextCD40 ligand has been suggested to play a pathogenic role in atherogenesis and coronary artery disease progression. Clinical studies suggest that intravenous (IV) abciximab administration attenuates the acute inflammatory response associated with percutaneous coronary intervention (PCI). The anti-inflammatory effects of intracoronary (IC) versus IV administration of abciximab have not been systematically investigated. We assessed changes in soluble CD40 ligand (sCD40L) concentrations in response to IC versus IV abciximab in patients with ST-elevation myocardial infarction (STEMI) undergoing thrombus-aspirating device during primary PCI.lld:pubmed
pubmed-article:19380134pubmed:languageenglld:pubmed
pubmed-article:19380134pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19380134pubmed:citationSubsetIMlld:pubmed
pubmed-article:19380134pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19380134pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19380134pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19380134pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19380134pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19380134pubmed:statusMEDLINElld:pubmed
pubmed-article:19380134pubmed:monthOctlld:pubmed
pubmed-article:19380134pubmed:issn1879-1484lld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:KaskiJuan...lld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:AvanzasPabloPlld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:Dominguez-Rod...lld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:Abreu-Gonzale...lld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:Samimi-FardSi...lld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:Bosa-OjedaFra...lld:pubmed
pubmed-article:19380134pubmed:authorpubmed-author:Marrero-Rodri...lld:pubmed
pubmed-article:19380134pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19380134pubmed:volume206lld:pubmed
pubmed-article:19380134pubmed:ownerNLMlld:pubmed
pubmed-article:19380134pubmed:authorsCompleteYlld:pubmed
pubmed-article:19380134pubmed:pagination523-7lld:pubmed
pubmed-article:19380134pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:meshHeadingpubmed-meshheading:19380134...lld:pubmed
pubmed-article:19380134pubmed:year2009lld:pubmed
pubmed-article:19380134pubmed:articleTitleIntracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.lld:pubmed
pubmed-article:19380134pubmed:affiliationDepartment of Cardiology, University Hospital of Canarias, Tenerife, Spain. adrvdg@hotmail.comlld:pubmed
pubmed-article:19380134pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19380134pubmed:publicationTypeRandomized Controlled Triallld:pubmed